Frederick Delboy, MD
Family Medicine · Chestertown, MDNPI 1245299932
Payments from drug & device makers
Across 438 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$895
- AbbVie$828
- Amgen$703
- Lilly USA, LLC$523
- Mylan Specialty L.p.$443
- Astellas Pharma US Inc$431
- plus $4K from 31 others
What the payments were for
- Food & beverage$7,20298%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 58 | $895 |
| AbbVie(2 entities) | 50 | $828 |
| Amgen(2 entities) | 34 | $703 |
| Lilly USA, LLC | 35 | $523 |
| Mylan Specialty L.p. | 23 | $443 |
| Astellas Pharma US Inc | 22 | $431 |
| GSK | 24 | $385 |
| Pfizer | 23 | $329 |
| Novo Nordisk | 26 | $325 |
| Johnson & Johnson | 16 | $322 |
| Boehringer Ingelheim | 12 | $220 |
| Exact Sciences | 11 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $198 |
| Daiichi Sankyo Inc. | 9 | $174 |
| Sunovion Pharmaceuticals Inc. | 13 | $169 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $164 |
| Bayer | 8 | $161 |
| Otsuka America Pharmaceutical, Inc. | 7 | $119 |
| Merck | 6 | $85 |
| Amarin Pharma, Inc. | 5 | $72 |
| Novartis | 4 | $69 |
| Philips North America LLC | 3 | $63 |
| Sanofi Pasteur Inc. | 3 | $60 |
| Ironshore Pharmaceuticals Inc. | 3 | $56 |
| Eisai Inc. | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Viatris Specialty LLC | 2 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Genentech USA, Inc. | 2 | $31 |
| Abbott | 2 | $29 |
| Alkermes, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Metacel Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$125
How this compares
$7,349 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $75,762 |
| XareltoRivaroxaban | 89 | $63,518 |
| JardianceEmpagliflozin | 70 | $55,735 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $32,596 |
| JanuviaSitagliptin Phosphate | 35 | $30,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,270 |
| TrulicityDulaglutide | 19 | $22,242 |
| FarxigaDapagliflozin Propanediol | 13 | $18,205 |
| MounjaroTirzepatide | 14 | $16,765 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 91 | $16,529 |
| OzempicSemaglutide | 16 | $16,066 |
| Spiriva RespimatTiotropium Bromide | 14 | $11,198 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,168 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,087 |
| LinzessLinaclotide | 20 | $10,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $329 | $80,878153 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $220 | $75,466102 claims |
| Johnson & JohnsonXarelto, Invokana | $322 | $71,245102 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $385 | $47,04677 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $523 | $39,00733 claims |
| MerckJanuvia | $85 | $30,11235 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $895 | $29,29231 claims |
| Novo NordiskOzempic | $325 | $16,06616 claims |
| AbbVieLinzess, Synthroid | $828 | $15,065101 claims |
| Astellas Pharma US IncMyrbetriq | $431 | $9,32115 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $198 | $4,29212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Chestertown
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.